{"id":45850,"date":"2022-07-06T13:01:49","date_gmt":"2022-07-06T11:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/"},"modified":"2022-07-06T13:01:49","modified_gmt":"2022-07-06T11:01:49","slug":"beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/","title":{"rendered":"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies"},"content":{"rendered":"
\n

\nBeiGene and InnoRNA will jointly research<\/i> a number of <\/i>mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs<\/i><\/b>\n<\/p>\n

\nBeiGene will also gain a non-exclusive license to InnoRNA\u2019s proprietary LNP Technology to support internal discovery efforts<\/i><\/b>\n<\/p>\n

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE<\/a> #BeiGene<\/a>–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics.\n<\/p>\n

<\/a><\/p>\n

\n\u201cAs a global biotechnology company, BeiGene is committed to delivering next-generation therapies through our own internal discovery engine and leveraging cutting-edge technology from experienced and innovative partners,\u201d said Lai Wang, Ph.D., Global Head of R&D at BeiGene. \u201cThis collaboration with InnoRNA advances and supports our research efforts in the important field of mRNA therapies while securing critical, proprietary delivery tools.\u201d\n<\/p>\n

\nUnder the terms of the agreement, InnoRNA will receive an upfront cash payment and will be eligible to receive additional payments based upon the achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties, for the mRNA-LNP research collaboration programs. BeiGene will hold exclusive global development and commercialization rights for the mRNA-LNP therapies jointly discovered by InnoRNA and BeiGene.\n<\/p>\n

\nInnoRNA will receive an additional upfront cash payment and is eligible for additional milestone payments for granting BeiGene non-exclusive license to its proprietary LNP Technology platform.\n<\/p>\n

\n\u201cWe are very excited to partner with BeiGene to discover and develop innovative mRNA therapies as well as contribute our LNP technology to BeiGene\u2019s internal research,\u201d said Linxian Li, Ph.D., Founder and Chief Executive Officer of InnoRNA. \u201cAs evidenced by the success of multiple Covid-19 vaccines, mRNA and LNPs will likely play a major role in the future of drug development, potentially in broad fields beyond vaccines. Joining this collaboration with BeiGene represents a big step forward toward this vision for our company.\u201d\n<\/p>\n

\nAbout InnoRNA
\n
<\/b>InnoRNA is a platform-based biotechnology company focused on developing innovative mRNA and LNP technologies to produce therapeutic proteins rapidly and accurately in cells. Faced with the challenge of delivering mRNA into the right cells, the existing carriers have been unable to maximize the potential of mRNA as a therapeutic tool to generate disease-fighting proteins. InnoRNA developed the proprietary Diversity-Oriented LNP platform to deliver mRNA safely and effectively into the cell of interest. The commercialization of this innovation presents a revolutionary step towards delivering effective and safe clinical mRNA treatments for societies everywhere. For more information, please visit our website at www.innorna.com<\/a>.\n<\/p>\n

\nAbout BeiGene
\n
<\/b>BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents. To learn more about BeiGene, please visit www.beigene.com<\/a> and follow us on Twitter at @BeiGeneGlobal.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the plan of future development of mRNA therapies using the licensed technology; potential payments to InnoRNA, the potential of the licensed technology; and the parties\u2019 commitments and the potential benefits of the collaboration, internal discovery and development plans and BeiGene\u2019s plans, commitments, aspirations and goals under the heading \u201cAbout BeiGene.\u201d Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services; BeiGene\u2019s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability; and the impact of the COVID-19 pandemic on BeiGene\u2019s clinical development, regulatory, commercial, manufacturing, and other operations, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in BeiGene\u2019s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact<\/b>
Kevin Mannix
\n
+1 240-410-0129
\n
ir@beigene.com<\/a>\n<\/p>\n

\nMedia Contact<\/b>
Kyle Blankenship
\n
+1 667-351-5176
\n
media@beigene.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs BeiGene will also gain a non-exclusive license to InnoRNA\u2019s proprietary LNP Technology to support internal discovery efforts CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45850","6":"format-standard","7":"category-industry"},"yoast_head":"\nBeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs BeiGene will also gain a non-exclusive license to InnoRNA\u2019s proprietary LNP Technology to support internal discovery efforts CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T11:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220705005854\/en\/1199527\/21\/BGNE_Logo_0821.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies\",\"datePublished\":\"2022-07-06T11:01:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/\"},\"wordCount\":908,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005854\\\/en\\\/1199527\\\/21\\\/BGNE_Logo_0821.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/\",\"name\":\"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005854\\\/en\\\/1199527\\\/21\\\/BGNE_Logo_0821.jpg\",\"datePublished\":\"2022-07-06T11:01:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005854\\\/en\\\/1199527\\\/21\\\/BGNE_Logo_0821.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005854\\\/en\\\/1199527\\\/21\\\/BGNE_Logo_0821.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/","og_locale":"en_US","og_type":"article","og_title":"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Pharma Trend","og_description":"BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs BeiGene will also gain a non-exclusive license to InnoRNA\u2019s proprietary LNP Technology to support internal discovery efforts CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE #BeiGene–BeiGene (NASDAQ: ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-06T11:01:49+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220705005854\/en\/1199527\/21\/BGNE_Logo_0821.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies","datePublished":"2022-07-06T11:01:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/"},"wordCount":908,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220705005854\/en\/1199527\/21\/BGNE_Logo_0821.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/","url":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/","name":"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220705005854\/en\/1199527\/21\/BGNE_Logo_0821.jpg","datePublished":"2022-07-06T11:01:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220705005854\/en\/1199527\/21\/BGNE_Logo_0821.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220705005854\/en\/1199527\/21\/BGNE_Logo_0821.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/beigene-announces-strategic-research-collaboration-with-innorna-to-jointly-discover-novel-mrna-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45850"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45850\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}